Paul Inman
Partner
Paul is a leading patent litigator, known for guiding life sciences clients through complex disputes and cross-border challenges with clarity and precision.
Partner
Paul is a leading patent litigator, known for guiding life sciences clients through complex disputes and cross-border challenges with clarity and precision.
Language - English
Jurisdiction - England & Wales
With a first degree in Molecular Biology and Biochemistry, Paul works with a diverse range of clients, from innovative start-ups to major global pharmaceutical and biotech companies. He is regularly instructed by organisations at the forefront of medical research, vaccine development, and advanced therapeutics, as well as those in sectors as varied as fashion, oil drilling, and consumer products. Clients value his ability to bring scientific understanding together with legal strategy, especially when the stakes are high and the issues are technically demanding.
Paul supports clients on patent infringement and revocation actions, portfolio management, and multi-jurisdictional litigation, including proceedings before the UK Patents Court, Unified Patents Court, and European Patent Office. He is known for navigating the intricacies of cross-border disputes and regulatory matters, ensuring clients can act decisively and protect their commercial interests worldwide. His experience extends to advising on regulatory work for European pharmaceutical bodies and coordinating litigation strategies across Europe, the US, and Asia-Pacific.
Clients turn to Paul when they need a steady hand in unfamiliar territory, whether that means steering a new vaccine to market, defending a blockbuster drug, or unlocking opportunities for breakthrough technologies. His approach is shaped by decades of experience and a genuine enthusiasm for helping clients achieve their goals, whatever the challenge.
Major Global Pharmaceutical company
Advising in relation to preliminary injunction and main proceedings in the Unified Patents Court (UPC) in relation to generic infringement of the client’s patent portfolio for one of its top-selling pharmaceutical products.
GlaxoSmithKline
A blockbuster dispute in the UK High Court, Court of Appeal and UPC against Pfizer involving a number of GSK's patents protecting its new vaccine for Respiratory Syncytial Virus, the most common worldwide cause of lower respiratory tract infections in infants.
Major Global Vaccine company
Advising in relation to patent portfolios relating to several aspects of Covid-19 mRNA vaccines.
Neurim Pharmaceuticals Limited
Successfully navigating a highly complex and unusual set of Court actions in both the UK Higher Courts and the EPO, concerning infringement of several patents, involving highly novel issues of estoppel and competition law, against a generic pharmaceutical company.
H. Lundbeck A/S
Successfully defending (against multiple Claimants over more than a decade) revocation proceedings brought against the client’s patent for its blockbuster anti-depressant drug from the High Court to the Supreme Court (House of Lords).
FujiFilm Kyowa Kirin Biologicals
Blockbuster dispute with AbbVie regarding FKB's biosimilar for AbbVie's $16 billion pa drug Humira, resulting in the first-ever Arrow declaration, which held that FKB's drug would have been obvious at the date of AbbVie's patents, protecting the client for all future claims of infringement.
Glaxo Group Limited
Successfully seeking and obtaining the second-ever Arrow declaration for GSK in a case concerning patents owned by Vectura plc claiming technology for formulation of the very small particles of asthma medication. GSK now avoid any further litigation from Vectura’s wide portfolio of patents.
Conor Medsystems Inc
Successfully invalidating a patent owned by Angiotech for taxol-eluting coronary stents allowing a small start-up entity and its groundbreaking technology, progress its business and become part of a major global stent organisation. This case went to the UK Supreme Court.
Coloplast
Acting for the client in relation to patents and Designs actions for its portfolio of ostomy and catheter related products.
Kennedy Trust for Rheumatology Research
Acting for the UK research institute in the first UK Biosimilar litigation relating to the rheumatoid arthritis treatment, Remicade, a monoclonal anti-TNF antibody.
